Co-Authors
This is a "connection" page, showing publications co-authored by NAIFA L BUSAIDY and RENATA FERRAROTTO.
Connection Strength
0.625
-
Recent advances and emerging therapies in anaplastic thyroid carcinoma. F1000Res. 2018; 7.
Score: 0.162
-
Surgery After BRAF-Directed Therapy Is Associated with Improved Survival in BRAFV600E Mutant Anaplastic Thyroid Cancer: A Single-Center Retrospective Cohort Study. Thyroid. 2023 04; 33(4):484-491.
Score: 0.058
-
Impact of Somatic Mutations on Survival Outcomes in Patients With Anaplastic Thyroid Carcinoma. JCO Precis Oncol. 2022 08; 6:e2100504.
Score: 0.055
-
Clinical Utility of Circulating Cell-Free DNA Mutations in Anaplastic Thyroid Carcinoma. Thyroid. 2021 08; 31(8):1235-1243.
Score: 0.051
-
Evaluation of Overall Survival in Patients With Anaplastic Thyroid Carcinoma, 2000-2019. JAMA Oncol. 2020 09 01; 6(9):1397-1404.
Score: 0.049
-
Complete Surgical Resection Following Neoadjuvant Dabrafenib Plus Trametinib in BRAFV600E-Mutated Anaplastic Thyroid Carcinoma. Thyroid. 2019 08; 29(8):1036-1043.
Score: 0.045
-
Circulating BRAF V600E Cell-Free DNA as a Biomarker in the Management of Anaplastic Thyroid Carcinoma. JCO Precis Oncol. 2018 Nov; 2:1-11.
Score: 0.043
-
Salvage pembrolizumab added to kinase inhibitor therapy for the treatment of anaplastic thyroid carcinoma. J Immunother Cancer. 2018 07 11; 6(1):68.
Score: 0.042
-
Neoadjuvant BRAF- and Immune-Directed Therapy for Anaplastic Thyroid Carcinoma. Thyroid. 2018 07; 28(7):945-951.
Score: 0.042
-
Real-World Experience with Targeted Therapy for the Treatment of Anaplastic Thyroid Carcinoma. Thyroid. 2018 01; 28(1):79-87.
Score: 0.040
-
Patterns of Treatment Failure in Anaplastic Thyroid Carcinoma. Thyroid. 2017 05; 27(5):672-681.
Score: 0.038